Ying Huang, Ph.D., has served as a member of our board of directors since July 2026. Dr. Huang is Chief Executive Officer (CEO) of K2 Therapeutics. Previously, he served as CEO of Legend Biotech Corporation from 2020 to 2026 and as its Chief Financial Officer from 2019 until 2022. Prior to Legend, Dr. Huang spent more than a decade as a biotechnology analyst, most recently as Managing Director and Head of Biotech Equity Research at BofA Securities, Inc. and previously at Wachovia, Credit Suisse, Gleacher and Barclays. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough in the Department of Chemical Research. Dr. Huang is also the co-author of multiple patents and peer-reviewed publications. Dr. Huang currently serves as a director of Quanta Therapeutics, Inc. and Third Arc Bio. Dr. Huang received his M.A., M.Phil. and Ph.D. in Chemistry from Columbia University. Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China.
